Effects of verapamil on the pharmacokinetics and metabolism of epirubicin

Cancer Chemotherapy and Pharmacology

Volumn 31, Issue 5, 1993, Pages 369-375

  Mross, K ^a   Hamm, K ^a   Hossfeld, D K ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; EPIRUBICIN; EPIRUBICIN GLUCURONIDE; EPIRUBICINOL GLUCURONIDE; UNCLASSIFIED DRUG; VERAPAMIL;

ARTICLE; BREAST CANCER; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG INTERACTION; DRUG METABOLISM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

CHEMOTHERAPY, ADJUVANT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; EPIRUBICIN; FEMALE; GLUCURONATES; HUMAN; SUPPORT, NON-U.S. GOV'T; VERAPAMIL;

EID: 0027479023     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/BF00686150     Document Type: Article

References (34)

1. Toxicity of novel anthracycline derivates towards normal myeloid bone marrow progenitor cells (CFU-GM) is not increased by verapamil
2. Clinical trial of continuous infusion verapamil, bolus vinblastine, and continuous infusion VP-16 in drug-resistant pediatric tumors
3. Biliary excretion and pharmacokinetics of 4′-epidoxorubicin in advanced cancer patients
4. Marked inter-patient variation in Adriamycin biotransformation to 7-deoxyaglycones: evidence from metabolites identified in serum
5. The consequences and significance of doxorubicin quinone reduction in vivo in tumor tissues
6. 4′-Epidoxorubicin plus verapamil in anthracycline-refractory cancer patients
7. Reversal of drug resistance in multiple myeloma with verapamil
8. Clinical pharmacokinetics of verapamil, nifedipine and diltiazem
9. Dependence of the cytostatic effect of Adriamycin on drug concentration and exposure time in vitro
10. Human daunorubicin reductases
11. Effect of verapamil on doxorubicin activity and pharmacokinetics in mice bearing resistant and sensitive tumors
12. Effect of verapamil on daunorubicin accumulation in Ehrlich ascites tumor cells
13. Effects of verapamil enantiomers and major metabolites on the cytotoxicity of vincristine and daunomycin in human lymphoma cell lines
14. Clinical pharmacokinetics of verapamil
15. Human breast carcinoma cell levels of MDR-1 (P-glycoprotein) transcripts correlate in vivo inversely and reciprocally with tumor progesterone receptor content
16. Reversal of multidrug resistance
17. The effect of verapamil on the pharmacokinetics of Adriamycin
18. Determination of verapamil and norverapamil in serum by high-performance liquid chromatography
19. Improved method for the determination of 4′-epidoxorubicin and seven metabolites in plasma by high-performance liquid chromatography
20. Verapamil pharmacokinetics and apparent hepatic and renal blood flow
21. A randomised trial of verapamil in addition to chemotherapy for small cell lung cancer
22. Adriamycin-enhanced membrane lipid peroxidation in isolated rat nuclei
23. Pharmacokinetics and metabolism of epirubicin and doxorubicin in humans
24. High-performance liquid chromatography of iodo-doxorubicin and fluorescent metabolites in plasma samples
25. Verapamil and Adriamycin in the treatment of drug-resistant ovarian cancer patients
26. Can verapamil induce second response in patients refractory to vincristine?
27. Comparative pharmacokinetics and metabolism of doxorubicin and epirubicin in patients with metastatic breast cancer
28. Quantitative determination of factors contributing to doxorubicin resistance in multidrug-resistant cells
29. Non-chemotherapeutic agents that potentiate chemotherapy efficacy
30. Pharmacokinetics and toxicity of two schedules of high dose epirubicin
31. Overcoming of vincristine resistance in p388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil
32. Chemotherapy in the multidisciplinary approach to soft tissue sarcomas
33. Pharmacokinetics of 4′-epi-doxorubicin in man